Immunotherapy and chemotherapy are not the same treatment. They fight cancer through fundamentally different mechanisms: chemotherapy uses drugs that directly kill fast-dividing cells, while immunotherapy helps your own immune system recognize and attack cancer. They differ in how they work, what side effects they cause, how quickly they show results, and how long those results last. In some cases, doctors use both together.
How Each Treatment Attacks Cancer
Chemotherapy targets cells that are in the process of dividing. It damages the genes inside a cell’s nucleus or interrupts the chemical processes that allow a cell to copy itself. Because cancer cells divide far more often than most normal cells, chemotherapy is more likely to kill them. But the drugs can’t distinguish between a cancer cell dividing and a healthy cell dividing, which is the root of most chemotherapy side effects.
Immunotherapy takes an entirely different approach. Instead of poisoning cancer cells directly, it trains or unleashes your immune system to do the job. Cancer cells often evade the immune system by disguising themselves as normal tissue or by pressing molecular “off switches” on immune cells. Immunotherapy drugs can block those off switches (these are called checkpoint inhibitors), or in some cases, immune cells are removed from your body, modified to better recognize a specific cancer, and then infused back in. The cancer-killing work is done by your own biology, not by the drug itself.
Side Effects Feel Very Different
Because chemotherapy attacks all rapidly dividing cells, it hits healthy tissue in your hair follicles, intestinal lining, and bone marrow. About 65% of patients experience hair loss. Over 70% deal with nausea and vomiting. Fatigue affects roughly 80% of patients, often because of anemia from bone marrow suppression. White blood cell counts drop, raising infection risk during treatment. These side effects tend to be immediate and noticeable, often starting within days of an infusion.
Immunotherapy side effects come from a different source: an immune system that’s been revved up and can sometimes turn on healthy organs. These are called immune-related adverse events, and they can affect the skin, gut, liver, lungs, thyroid, or other organs. The range runs from mild (a rash, mild fatigue, some diarrhea) to severe (inflammation of the lungs or liver that requires treatment with steroids or other drugs to calm the immune response). Overall, immunotherapy is associated with fewer acute side effects than chemotherapy, but the immune-related reactions require close monitoring because they can escalate.
Response Time and Durability
Chemotherapy often produces visible changes in tumor size relatively quickly. Imaging scans and blood markers can show measurable shrinkage within the first few cycles. Immunotherapy typically takes longer. Because the treatment is essentially teaching your immune system to fight the cancer rather than attacking it directly, it can take weeks or months to see a measurable response. In some cases, tumors even appear larger on early scans because immune cells are flooding into the tumor before shrinking it.
Where immunotherapy often shines is in durability. When it works, the response can last much longer than chemotherapy because the immune system develops a kind of memory against the cancer. A five-year analysis from Johns Hopkins found that when immunotherapy was added to chemotherapy before lung cancer surgery, 24% of patients achieved complete remission, with no detectable tumor remaining. Among those patients, five-year survival reached 95%. Chemotherapy alone rarely produces that kind of long-lasting clearance. Oncologists sometimes describe this as the “tail of the curve,” referring to the portion of patients who remain in remission years after treatment ends.
They’re Often Used Together
For many cancers, the standard of care now combines both treatments. Chemotherapy can kill large numbers of cancer cells quickly, and the debris from those dying cells can actually help the immune system recognize what it should be targeting. This makes immunotherapy more effective when given alongside or after chemotherapy.
Combination regimens are currently approved for a wide range of cancers, including several types of lung cancer (both small cell and non-small cell), triple-negative breast cancer, bladder cancer, head and neck cancers, esophageal cancer, gastric cancer, cervical cancer, biliary tract cancer, and endometrial cancer. The list continues to grow as clinical trials report results. If you’re being treated for one of these cancers, there’s a real chance your treatment plan includes both chemotherapy and immunotherapy, sometimes in the same infusion session.
What Treatment Looks Like Day to Day
Both treatments are most commonly given through an IV, and both are usually administered in an outpatient setting, meaning you go to a clinic or hospital infusion center and go home the same day. Both are given in cycles, with periods of treatment followed by rest periods that give your body time to recover.
The schedules vary. Chemotherapy cycles often run every two to three weeks, with treatment days followed by recovery weeks. Immunotherapy schedules depend on the specific drug and your cancer type. Some immunotherapy drugs are given every two weeks, others every three or six weeks. Treatment duration also differs: chemotherapy is typically given for a set number of cycles (often four to six), while immunotherapy may continue for a year or two, or even longer if it’s working and side effects are manageable.
One practical difference worth knowing: chemotherapy side effects like nausea and fatigue tend to follow a predictable pattern within each cycle, often peaking a few days after infusion and gradually improving before the next round. Immunotherapy side effects can appear at any point during treatment, sometimes months after starting, which is why ongoing monitoring with blood tests and check-ins is a routine part of the process.
Not Every Cancer Responds to Both
Chemotherapy has been a cornerstone of cancer treatment for decades and works across a broad range of cancer types. Immunotherapy is more selective. It tends to work best in cancers that have many genetic mutations (which give the immune system more targets to recognize) or cancers that rely heavily on immune evasion to survive. Melanoma, lung cancer, and bladder cancer were among the first to show strong responses to immunotherapy. Other cancers, like certain pancreatic or brain cancers, have been much harder to treat with immunotherapy alone.
Your oncologist considers the specific type and stage of your cancer, its molecular features, and your overall health when deciding whether chemotherapy, immunotherapy, or both are the right approach. In cancers where immunotherapy is effective, it has genuinely changed survival expectations for many patients. But it’s not a universal replacement for chemotherapy. They remain distinct tools with different strengths, and for a growing number of cancers, the best outcomes come from using them together.